Xenon Pharmaceuticals
XENE
206 hedge funds and large institutions have $2.6B invested in Xenon Pharmaceuticals in 2025 Q2 according to their latest regulatory filings, with 42 funds opening new positions, 77 increasing their positions, 55 reducing their positions, and 40 closing their positions.
40% more repeat investments, than reductions
Existing positions increased: 77 | Existing positions reduced: 55
17% more call options, than puts
Call options by funds: $11.4M | Put options by funds: $9.75M
8.11% more ownership
Funds ownership: 100.23% → 108.34% (+8.1%)
5% more first-time investments, than exits
New positions opened: 42 | Existing positions closed: 40
1% more capital invested
Capital invested by funds: $2.58B → $2.6B (+$26M)
0% more funds holding
Funds holding: 206 → 206 (0)
29% less funds holding in top 10
Funds holding in top 10: 14 → 10 (-4)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BlackRock
New York
|
+$109M |
| 2 |
Holocene Advisors
New York
|
+$59M |
| 3 |
State Street
Boston,
Massachusetts
|
+$35.1M |
| 4 |
Geode Capital Management
Boston,
Massachusetts
|
+$29.4M |
| 5 |
B
Braidwell
Stamford,
Connecticut
|
+$29.2M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Wellington Management Group
Boston,
Massachusetts
|
-$52.7M |
| 2 |
Capital World Investors
Los Angeles,
California
|
-$51.2M |
| 3 |
SC
Samlyn Capital
New York
|
-$34.1M |
| 4 |
T. Rowe Price Investment Management
Baltimore,
Maryland
|
-$23.5M |
| 5 |
LGM
Logos Global Management
San Francisco,
California
|
-$21.8M |
XENE Hedge Fund Activity: Q2 2025 in Review
206 of the 7,596 institutional investors tracked by Wall St. Rank reported a position in Xenon Pharmaceuticals (XENE) for Q2 2025, worth a combined $2.6B — up 1% from $2.58B a quarter earlier.
Buyers outnumbered sellers: 42 funds opened new XENE positions and 40 closed out — a net gain of 2 holders — while 77 added to existing stakes and 55 trimmed.
The largest buyer was BlackRock, adding an estimated $109M. The largest seller was Wellington Management Group, cutting an estimated $52.7M.
- 206 institutional investors held Xenon Pharmaceuticals (XENE) as of Q2 2025, unchanged from Q1 2025.
- Funds reported $2.6B of Xenon Pharmaceuticals stock for Q2 2025, up 1% quarter-over-quarter.
- 42 funds opened new Xenon Pharmaceuticals positions in Q2 2025 and 40 closed out, a net change of +2 holders.
- The largest Xenon Pharmaceuticals buyer in Q2 2025 was BlackRock, an estimated $109M added.
- The largest Xenon Pharmaceuticals seller in Q2 2025 was Wellington Management Group, an estimated $52.7M sold.
Based on aggregated 13F filings for Q2 2025.